SAB Biotherapeutics announced the company has entered into an exclusive manufacturing services agreement with Emergent BioSolutions Inc. Emergent will provide contract development and manufacturing (CDMO) services to produce SAB's fully-human polyclonal antibody products. Currently, SAB has clinical-stage programs in pan-influenza treatment, treatment of acute and recurrent C. diff., prevention of Type 1 diabetes, and discovery assets in immunology and oncology. Under the terms of the agreement, Emergent will provide end-to-end Good Manufacturing Practice (cGMP) manufacturing services to SAB, including process development and manufacturing clinical investigational drug product to support SAB's clinical programs, and commercial manufacturing services upon regulatory approval of SAB's therapeutics.

The agreement also provides the opportunity for Emergent to utilize SAB's novel DiversitAb™ platform, the only one in the world that produces fully-human polyclonal antibodies utilizing transchromosomic cows, for future development of undisclosed programs. Financial details of the agreement were not disclosed.